Ocular Oncology and the Study of Rare Cancers

American Cancer Society. Cancer Facts and Figures. American Cancer Society: Atlanta, Ga; 2002.

Diener-West M. , Moy C.S. Epidemiology of uveal melanoma: patient characteristics, risk factors and predisposing elements. In: Albert D.M. , Polans A.R. , eds. Ocular Oncology. New York, NY: Marcel Dekker Inc; 2003, chapter 3.

The Collaborative Ocular Melanoma Study-Quality of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma. Arch Ophthalmol. 2003; 121: 1010–1020.

Edwards S.J.L. , Lilford R.J. , Braunholtz D. Why “underpowered” trials are not necessarily unethical. Lancet. 1997; 350: 804–807.

Halpern S.D. , Karlawish J.H. , Berlin J.A. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002; 288: 358–362.

Tan S-B , Dear K.B.G. , Bruzzi P. Strategy for randomized clinical trials in rare cancers. BMJ. 2003; 327: 47–49.

Goss C.H. , Mayer-Hamblett N. , Kronmal R.A. The cystic fibrosis therapeutics development network (CFTDN): a paradigm of a clinical trials network for genetic and orphan disease. Adv Drug Deliv Rev. 2002; 54: 1505–1528.

Beck R.W. Clinical research in pediatric ophthalmology: the Pediatric Eye Disease Investigator Group. Curr Opin Ophthalmol. 2002; 13: 337–340.

The Pediatric Eye Disease Investigator Group. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol. 2003; 121: 603–611.